Avelumab and Merkel Cell Carcinoma: Therapeutic Mechanism and Risk Considerations

From General Skin Health to Specialized Exposure Awareness

The legacy of general health and science communication has long emphasized foundational wellness principles, including skin care as a component of anti-aging strategies. Public discourse on skin health historically focused on preventive measures such as sun protection, hydration, and topical regimens to maintain dermal integrity. This broad educational framework served to empower individuals with actionable knowledge for personal health maintenance, often without delving into specific pharmacological or environmental risk factors. As scientific understanding advances, the scope of health information must expand to address emerging intersections between therapeutic agents and occupational environments. The transition from general wellness guidance to specialized exposure awareness requires acknowledging that certain medical treatments, while beneficial in controlled contexts, may introduce new considerations for patient populations. In particular, the administration of immunomodulatory therapies in clinical settings raises questions about their potential interactions with underlying cellular processes. This bridge concept moves the discussion from universal skin health tips toward a more focused examination of how specific pharmaceutical exposures—such as those encountered in oncology practice—might relate to subsequent disease development. The occupational concern centers on healthcare workers and patients who handle or receive biologic agents, where understanding exposure pathways becomes critical for risk assessment. By extending the heritage of health education into this specialized domain, we maintain the original commitment to informed decision-making while addressing contemporary challenges in therapeutic safety.

Avelumab: Mechanism of Action and Therapeutic Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It was approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096; https://pubmed.ncbi.nlm.nih.gov/33439294). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096). This made avelumab the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096). Merkel cell carcinoma pathophysiology involves two primary etiologies: approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment for metastatic MCC includes anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which compared with conventional chemotherapy show better overall response rates and longer duration of responses (https://pubmed.ncbi.nlm.nih.gov/34445385). However, approximately 50% of patients do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385).

Immune-Related Adverse Events and Risk Context

Avelumab, as an anti-PD-L1 inhibitor, is known to cause overactivation of the immune system, leading to irAEs (https://pubmed.ncbi.nlm.nih.gov/31543781). Reported adverse effects include hypercalcaemia secondary to reactivation of sarcoidosis, which was managed with corticosteroids to full resolution while avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781). The mechanistic pathway linking avelumab to Merkel cell carcinoma pathophysiology is not one of causation but rather of therapeutic modulation. Avelumab blocks PD-L1 on tumor cells and immune cells, thereby enhancing T-cell responses against MCC cells (https://pubmed.ncbi.nlm.nih.gov/29799096). This immune checkpoint inhibition can lead to tumor regression, as evidenced by response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381). However, the same mechanism can also trigger irAEs, including hypercalcaemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781). For patients who become refractory to avelumab, alternative treatments such as combined ipilimumab and nivolumab have shown activity, with three out of five patients in a small study responding according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294). A multicenter study of the prospective skin cancer registry ADOREG further confirmed the efficacy of ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381). Regarding risk anchors, the adequacy of warnings about avelumab and Merkel cell carcinoma is reflected in the approved labeling, which specifies its use for metastatic MCC based on clinical trial data (https://pubmed.ncbi.nlm.nih.gov/29799096). The warnings primarily address immune-related adverse events, which are a known class effect of checkpoint inhibitors, rather than a direct causation of MCC. Causation-related considerations for affected patients focus on the fact that avelumab is used to treat MCC, not to cause it. The timeline between exposure and documented harm involves the development of irAEs during treatment, such as hypercalcaemia from sarcoidosis reactivation, which occurred during avelumab therapy and resolved with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781). For patients who do not respond or become refractory, the timeline for disease progression may vary, but alternative immunotherapies can be considered (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). Overall, the evidence supports avelumab as a therapeutic agent for MCC, with risks primarily related to immune-related adverse events rather than triggering the disease itself.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is used to treat Merkel cell carcinoma (MCC), not cause it. It is an immune checkpoint inhibitor that blocks PD-L1 to enhance T-cell responses against MCC cells (https://pubmed.ncbi.nlm.nih.gov/29799096). The primary risks are immune-related adverse events, not causation of the disease.

What are the common side effects of avelumab in MCC treatment?

Common side effects include immune-related adverse events (irAEs) such as hypercalcaemia secondary to reactivation of sarcoidosis, which can be managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781). Approximately 50% of patients may not respond or develop irAEs due to mechanisms like down-regulation of MHC complexes (https://pubmed.ncbi.nlm.nih.gov/34445385).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.